Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INFOGRAPHIC: 72 US IPOs gross $5.7bn in 2014; values rising in 2015

This article was originally published in Scrip

Executive Summary

In 2014, 72 biotechnology firms that develop drugs, biologics and gene, stem or cell therapies grossed $5.7bn from initial public offerings in the US with most companies ending the year with stock values well above their IPO price – and values have risen higher in 2015.

You may also be interested in...



Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter

Venture capital investment in biopharmaceutical firms for the first half of 2017 show that this year is on track to exceed 2016 levels. Recent financings include two $50m Series C rounds for two different companies developing later-stage drugs for itching: Trevi and Menlo Therapeutics.

With $850m, Nuvation Aims To Speed Novel Cancer Drugs To Patients

Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.

Finance Watch: Have Investors Reached IPO Fatigue?

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel